Hospital

It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.

The first fully approved vaccine for COVID-19 will be marketed under the name Comirnaty.

Prescription labels have a lot of details on them, which can make it difficult for patients to find and use important information.

Median disease-free survival was nearly twice as long among patients with urothelial carcinoma who received nivolumab compared with placebo.

Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.

STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

The agents that have been evaluated and approved, and those that are coming in the pipeline, make for an exciting time to consider directed therapies.

This week’s recommendation by the Biden administration for booster shots to combat COVID-19 is a call to action for pharmacists to get ready for the upcoming flurry of activity.

The study results indicated a nearly 9-fold increase in likelihood of survival without ventilation (SWOV) among this population, compared to a 2.5-fold increased likelihood of SWOV in the overall population.

The lower the glomerular filtration rate, the lower the stage, the worse kidney disease is.

The investigators analyzed a panel of antibodies generated in response to the Pfizer COVID-19 vaccine and found that delta was unable to evade all but 1 of the antibodies tested.

In clinical trials, empagliflozin significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25%.

Specialty pharmacists’ roles have grown in new and exciting ways in recent years, and those changes have directly impacted health outcomes for all specialty patients, including patients with HIV.

Widespread COVID-19 booster shot administration is pending FDA approval and recommendation by the Advisory Committee on Immunization Practices.

The continued approval for this indication may be subject upon verification and description of clinical benefit in a confirmatory trial.

Approved by the FDA on June 29, 2020, the pertuzumab, trastuzumab, and hyaluronidase-zzxf combination therapy with chemotherapy offers several advantages to the standard treatment of pertuzumab plus trastuzumab with chemotherapy for breast cancers with HER2 overexpression.

These findings could lead to improved therapies and prolonged survival for patients with metastatic TNBC, according to the study authors.

English discussed the challenges and highlights of her time in the trial, in addition to what she feels health care professionals should learn from her own treatment experience.

Dennis Wright, senior director of product marketing for Central Pharmacy Compounding and Dispensing at Omnicell, discusses methods of addressing the rising rate of hospital pharmacist burnout through automation and technology-enabled services.

What many preceptors may not realize is that in addition to learning about practice settings, all graduates of pharmacy schools in the United States must also be able to demonstrate leadership, innovation, and entrepreneurship.

Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected.

Non-alcoholic steatohepatitis is the most severe form of non-alcoholic fatty liver disease.

Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.

This has caused an ongoing problem with mistrust in many vaccines and medications, since there is still uncertainty surrounding how they affect other races and ethnicities.

Specific infection-fighting cells of the immune system found to be downregulated, offering a potential clue to the cause of prolonged COVID-19 illness in children.

The FDA has granted orphan drug designation to CFT7455 for the treatment of multiple myeloma, according to a press release from manufacturer C4 Therapeutics.

The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.

An announcement from CDC officials recommending COVID-19 boosters for all adults could come as soon as this week, although doses would only be widely administered once the FDA formally approved the vaccines.